去纤苷治疗肝小静脉闭塞病患者疗效好吗？

Is defibrotide (sodium defibrotide) effective in treating patients with hepatic veno-occlusive disease? Studies have shown that defibrotide (defibrotide sodium) mainly exerts various biological functions by affecting vascular endothelial cell response and platelet activity. Defibrotide (defibrotide sodium) contains nucleic acid aptamers that can interact with adenosine A1 and A2 receptors, thereby reducing the response of endothelial cells to injury and protecting vascular endothelium. 

Defibrotide (sodium defibrotide) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide (sodium defibrotide) can act on these receptors to produce a variety of downstream effects. Defibrotide (defibrinated sodium) can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells. 

In addition, defibrotide (defibrotide sodium) can also promote the release of prostaglandin I2 (PGI2) and prostaglandin E2 (PGE2), thereby causing blood vessel dilation, inhibiting platelet aggregation, and reducing ischemic damage. Studies have shown that defibrotide can significantly increase the expression of thrombin regulatory protein (TM) and tissue factor pathway inhibitors to produce anticoagulant effects. The most common side effects (incidence ≥10% and independent causal relationship) with treatment with defibrotide (defibrotide sodium) are hypotension, diarrhea, vomiting, nausea, and epistaxis. 

For some patients with leukemia and lymphoma, hematopoietic stem cell transplantation (HSCT) is the only hope to cure the disease and regain health. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. The launch of defibrotide (defibrotide sodium) has brought new treatment hope to the majority of patients and has broad development and treatment prospects. Please consult Medical Companion Travel for specific questions.